The PennZone

  • Home
  • Non-profit
  • Health
  • Books
  • Entertainment
  • Business
  • Marketing
  • Legal
  • Automotive

ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
The PennZone/10350522

Trending...
  • Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
  • A New Era Of Social Networking Is Here !
  • Poetry Quarterly Returns in Print With Its Fall 2026 Issue, Featuring 42 Poets
ClearSight Therapeutics, Inc.
USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.

DALLAS - PennZone -- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance for Ophthalmic Formulation Technology for unmet ocular diseases

Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications


DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."

The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.

More on The PennZone
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • Veteran Antiques Expert John Swahn Releases New Book: The Truth About Antiques
  • Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy
  • Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus

"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."

"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."

In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.

More on The PennZone
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently

About ClearSight Therapeutics

ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.

Media Contact

ClearSight Therapeutics
info@clearsighttx.com
972-983-7761

Contact
ClearSight Therapeutics, Inc.
Patrick Smale
***@clearsighttx.com


Source: ClearSight Therapeutics, Inc.
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Meals on Wheels of the Greater Lehigh Valley Raises Over $50,000 to Help Feed Local Seniors
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
  • Coach Bulinda Wright Advances To Top Five In National 'Top Host 2026 Competition'
  • Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
  • Feldman Shepherd Named as 2027 'Best Law Firm' by Best Lawyers -- Tier 1 National & Philadelphia
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
  • Corner Property Management AAMC Awarded Community Management Contract for Belvidere at Doyle Square
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
  • TrueDriveCost Launches Free Calculators for the Real Cost of Owning a Car
  • A New Era Of Social Networking Is Here !
  • Poetry Quarterly Returns in Print With Its Fall 2026 Issue, Featuring 42 Poets
  • HIRO Ostomy Belt Launch by Richard O'Hamill
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand

Popular on PennZone

  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection - 160
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 142
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type - 132
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 130
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta - 127
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of - 125
  • Corner Property Management AAMC Expands Presence with Clover Mill Management Agreement - 120
  • Sycamore Dove Releases "Loving Every Moment" - 109
  • Keystone Consulting Engineers Marks Next Chapter of Growth with Refreshed Brand - 103
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 102

Similar on PennZone

  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us